Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
3 studies found for:    9196156 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Targeted chemotherapy prior to surgery;   Drug: standard FOLFIRINOX chemotherapy prior to surgery;   Drug: Gemcitabine after surgery;   Other: No additional therapy after surgery;   Drug: Targeted chemotherapy after surgery;   Radiation: Chemoradiotherapy (cXRT)
2 Terminated Lag-3 and Gemcitabine for Treatment of Advanced Pancreas Cancer
Condition: Pancreatic Neoplasms
Interventions: Drug: Gemcitabine;   Biological: LAG-3
3 Completed Phase III of Gemcitabine Vs TS-1 Vs Gemcitabine Plus TS-1 in Pancreatic Cancer
Condition: Pancreatic Cancer
Interventions: Drug: Gemcitabine plus TS-1;   Drug: TS-1;   Drug: Gemcitabine

Indicates status has not been verified in more than two years